Cellectis (CLLS) Assets Average (2014 - 2026)
Cellectis (CLLS) posted quarterly Assets Average of $307.0 million for Q1 2026, down 17.89% year-over-year from $373.8 million in Q1 2025, and down 8.07% quarter-over-quarter from $333.9 million in Q4 2025.
Cellectis (CLLS) Assets Average (2014 - 2026) Analysis & Trends
Cellectis' Assets Average history runs 13 years deep, the most recent figure standing at $307.0 million for Q1 2026.
- In Q1 2026, Assets Average fell 17.89% year-over-year to $307.0 million; the TTM figure through Mar 2026 stood at $307.0 million (down 17.89% YoY), while the FY2025 annual figure was $354.1 million, down 1.33% from the prior year.
- Assets Average for Q1 2026 stood at $307.0 million, down from $333.9 million in the prior quarter.
- The five-year high for Assets Average was $401.5 million in Q3 2024, with the low at $218.7 million in Q3 2023.
- The 5-year median for Assets Average is $334.0 million (2022), against an average of $323.2 million.
- The sharpest annual moves came in 2022 and 2024: Assets Average sank 31.97% in 2022, then jumped 83.6% in 2024.
- Cellectis' Assets Average stood at $270.4 million in 2022, then gained by 0.59% to $272.0 million in 2023, then jumped by 43.28% to $389.7 million in 2024, then retreated by 14.33% to $333.9 million in 2025, then fell by 8.07% to $307.0 million in 2026.
- Business Quant data shows CLLS's Assets Average at $307.0 million in Q1 2026, $333.9 million in Q4 2025, and $348.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Cellectis | 306.61 Mn | 120.95 Mn | - | 306.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 306.95 Mn |
| Dec 31, 2025 | 333.88 Mn |
| Sep 30, 2025 | 348.51 Mn |
| Jun 30, 2025 | 359.03 Mn |
| Mar 31, 2025 | 373.82 Mn |
| Dec 31, 2024 | 389.71 Mn |
| Sep 30, 2024 | 401.51 Mn |
| Jun 30, 2024 | 380.80 Mn |
| Mar 31, 2024 | 344.36 Mn |
| Dec 31, 2023 | 271.99 Mn |
| Sep 30, 2023 | 218.69 Mn |
| Jun 30, 2023 | 239.54 Mn |
| Mar 31, 2023 | 256.31 Mn |
| Dec 31, 2022 | 270.40 Mn |
| Sep 30, 2022 | 300.23 Mn |
| Jun 30, 2022 | 334.04 Mn |
| Mar 31, 2022 | 364.63 Mn |
| Dec 31, 2021 | 397.48 Mn |
| Sep 30, 2021 | 435.23 Mn |
| Jun 30, 2021 | 450.14 Mn |